Terns Pharmaceuticals Return on Equity

Terns Pharmaceuticals (TERN) currently reports a ROE of -9.56%. That is below the Healthcare sector average of 29.03%. Use the charts on this page to explore Terns Pharmaceuticals's ROE history and peer comparisons.

Terns Pharmaceuticals's ROE of -9.56% is lower than the Healthcare sector average of 29.03%. That is roughly 132.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Terns Pharmaceuticals's current -9.56% should be judged against Healthcare norms (sector average: 29.03%) and against TERN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -9.56%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.03%. From there, open related valuation or income-statement pages for Terns Pharmaceuticals, and consider following TERN for alerts when major investors trade the stock.

Terns Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -9.56% versus a sector average near 29.03%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TERN with unrelated industries.